Sifting through countless of stocks in the Health Care Equipment & Supplies industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in RxSight, Inc., Bio-Rad Laboratories or Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how RxSight, Inc., Bio-Rad Laboratories and Inc. compare based on key financial metrics to determine which better meets your investment needs.

About RxSight, Inc., Bio-Rad Laboratories and Inc.

RxSight, Inc., a commercial-stage medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company’s RxSight system includes RxSight Light Adjustable Lens (LAL), an intraocular lens made of photosensitive material that changes shape in response to specific patterns of ultraviolet, which can be adjusted to improve uncorrected visual acuity; and RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. RxSight, Inc. was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. The company was incorporated in 1997 and is headquartered in Aliso Viejo, California.

Bio-Rad Laboratories, Inc. develops, manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, Latin America, and internationally. It operates through two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantify biological materials, including cells, proteins, and nucleic acids used in research and biopharmaceutical laboratory environments, as well as for biopharmaceutical manufacturing, quality control process, food safety, and science education applications. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology companies, food producers, and testing laboratories. Its Clinical Diagnostics segment designs, manufactures, markets, and supports diagnostic test systems, informatics systems, test kits, and specialized quality controls for clinical, hospital, diagnostic reference, and transfusion and physician office laboratories, as well as software. The company offers its products through its direct commercial organization, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.

Latest Health Care Equipment & Supplies and RxSight, Inc., Bio-Rad Laboratories, Inc. Stock News

As of July 31, 2026, RxSight, Inc. had a $249.4 million market capitalization, compared to the Health Care Equipment & Supplies median of $337.2 million. RxSight, Inc.’s stock is down 42.3% in 2026, up 15.8% in the previous five trading days and down 24.5% in the past year.

Currently, RxSight, Inc. does not have a price-earnings ratio. RxSight, Inc.’s trailing 12-month revenue is $127.5 million with a -36.6% net profit margin. Year-over-year quarterly sales growth most recently was -18.5%. Analysts expect adjusted earnings to reach $-0.668 per share for the current fiscal year. RxSight, Inc. does not currently pay a dividend.

As of July 31, 2026, Bio-Rad Laboratories, Inc. had a $8.6 billion market cap, putting it in the 75th percentile of all stocks. Bio-Rad Laboratories, Inc.’s stock is up 7.4% in 2026, up 3.5% in the previous five trading days and up 30.15% in the past year.

Currently, Bio-Rad Laboratories, Inc.’s price-earnings ratio is 52.2. Bio-Rad Laboratories, Inc.’s trailing 12-month revenue is $2.6 billion with a 6.5% net profit margin. Year-over-year quarterly sales growth most recently was 1.1%. Analysts expect adjusted earnings to reach $9.002 per share for the current fiscal year. Bio-Rad Laboratories, Inc. does not currently pay a dividend.

How We Compare RxSight, Inc., Bio-Rad Laboratories and Inc. Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at RxSight, Inc., Bio-Rad Laboratories and Inc.’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

RxSight, Inc., Bio-Rad Laboratories and Inc. Growth Grades

Company	Ticker	Growth
RxSight, Inc.	RXST	F
Bio-Rad Laboratories, Inc.	BIO	D

The foundation of growth investing is seeking out stocks of companies exhibiting strong, consistent and prolonged growth that is expected to continue into the future.

In order to compute the growth score and assign it a letter grade, the percentile ranks for each of three components‐consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations‐must be determined. These three rank figures are added together, and the sum is ranked against the entire stock universe to arrive at a company’s Growth Score to create an equal distribution of grades.

The companies in the bottom 20% of the stock universe receive Growth Grades of F, considered to be very weak, while those in the top 20% receive A grades, which are considered very strong.

RxSight, Inc. has a Growth Score of 18, which is Very Weak. Bio-Rad Laboratories, Inc. has a Growth Score of 25, which is Weak.

The Growth Stock Winner: No Clear Winner

Neither RxSight, Inc., Bio-Rad Laboratories or Inc. has a high enough Growth Grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if RxSight, Inc., Bio-Rad Laboratories or Inc. is the better investment when it comes to sustainable growth.

RxSight, Inc., Bio-Rad Laboratories and Inc.’s Quality Grades

Company	Ticker	Quality
RxSight, Inc.	RXST	C
Bio-Rad Laboratories, Inc.	BIO	B

Like the Value Grade, AAII’s A+ Investor Quality Grade comes from the percentile rank of key metrics. Specifically, the Quality Score is the percentile rank of the average of the percentile ranks of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and the F-Score.

The score is variable, meaning it can consider all eight measures or, should any of the eight measures not be valid, the remaining measures that are valid. To be assigned a Quality Score, stocks must have a valid (non-null) measure and corresponding ranking for at least four of the eight quality measures.

The Quality Score is used to assess the underlying “quality” of a particular stock. A higher-quality stock possesses traits associated with upside potential and reduced downside risk. Backtesting of the Quality Grade shows that stocks with higher grades, on average, outperformed stocks with lower grades over the period of 1998 through 2019.

Stocks receive better grades (higher scores) for having higher scores for the quality subcomponents and worse grades (lower scores) for lower scores for the subcomponents.

RxSight, Inc. has a Quality Score of 56, which is Average. Bio-Rad Laboratories, Inc. has a Quality Score of 76, which is Strong.

The Quality Grade Winner: Bio-Rad Laboratories, Inc.

As you can clearly see from the Quality Grade breakdown above, Bio-Rad Laboratories, Inc. has a better overall quality grade than RxSight, Inc.. For investors who are looking for companies with higher quality than others in the same industry, Bio-Rad Laboratories, Inc. could be a good stock to add to their portfolios. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

RxSight, Inc., Bio-Rad Laboratories and Inc.’s Estimate Revisions Grades

Company	Ticker	Earnings Estimate
RxSight, Inc.	RXST	C
Bio-Rad Laboratories, Inc.	BIO	D

Earnings estimate revisions scores consider the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, positive surprises beget further positive surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Estimate revisions offer an indication of what analysts are thinking about the short-term prospects of a firm. Estimate revisions are based on the statistical significance of a firm’s last two quarterly earnings surprises and the percentage change in its consensus estimate for the current fiscal year over the past month and past three months.

RxSight, Inc. has a Earnings Estimate Score of 48, which is Neutral. Bio-Rad Laboratories, Inc. has a Earnings Estimate Score of 24, which is Negative.

The Earnings Estimate Revisions Stock Winner: No Clear Winner

Neither RxSight, Inc., Bio-Rad Laboratories or Inc. has an Earnings Estimate Revisions Grade that could be considered a “winner.” Investors considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if RxSight, Inc., Bio-Rad Laboratories or Inc. is the better investment when it comes to estimate revisions.

Other RxSight, Inc., Bio-Rad Laboratories and Inc. Grades

In addition to Estimate Revisions, Growth and Quality, A+ Investor also provides grades for Value and Momentum.

Momentum grades help uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming.

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection. Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether RxSight, Inc., Bio-Rad Laboratories and Inc. pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, RxSight, Inc., Bio-Rad Laboratories or Inc. Stock?

Overall, RxSight, Inc. stock has a Growth Score of 18, Estimate Revisions Score of 48 and Quality Score of 56.

Bio-Rad Laboratories, Inc. stock has a Growth Score of 25, Estimate Revisions Score of 24 and Quality Score of 76.

Comparing RxSight, Inc., Bio-Rad Laboratories and Inc.’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.